Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6839201 | 0.85 | FOLH1 (0.50) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL11141533 | 0.85 | FOLH1 (0.50) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL264745 | 0.85 | FOLH1 (0.50) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL17374631 | 0.85 | IRAK4 (0.47) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL725761 | 0.85 | GABRA1 (0.50) | IRAK4ALOX15ALOX12KMT2AKDM4E | |
| SCHEMBL28766027 | 0.82 | CYP2D6 (0.43) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL4551989 | 0.82 | NOS3 (0.60) | CYP2C9HTR2ANOS3NOS1NOS2 | |
| SCHEMBL4792772 | 0.82 | NOS3 (0.60) | CYP2C9HTR2ANOS3NOS1NOS2 | |
| SCHEMBL9723651 | 0.81 | TAAR1 (0.44) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 | |
| SCHEMBL19285676 | 0.81 | GAA (0.49) | CYP2D6CYP2C9CYP2C19SLC6A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | Pharmapotheca A, Inc. | 2025-07-03 | — | — | US | disclosed |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | Pharmapotheca A Inc. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | CHEMAPOTHECA, LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | Pharmapotheca A, Inc. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | PHARMAPOTHECA, LLC (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | PHARMAPOTHECA, LLC (US) | 2021-02-04 | — | — | US | disclosed |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2020-11-12 | — | — | US | disclosed |
| EP-3478363-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | Chemapotheca LLC (US) | 2019-05-08 | — | — | EP | disclosed |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC | 2018-08-30 | — | — | US | disclosed |
| EP-2318126-B1 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | UNIV TEXAS (US) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017147375-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS | CHEMAPOTHECA, LLC (US) | 2017-08-31 | — | — | WO | disclosed |
| US-8017050-B2 | Water purification membranes with improved fouling resistance | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-09-13 | — | — | US | disclosed |
| CN-102149450-A | Water purification membranes with improved fouling resistance | UNIV TEXAS | 2011-08-10 | — | — | CN | disclosed |
| EP-2318126-A2 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2011005258-A1 | POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-01-13 | — | — | WO | disclosed |
| US-20100059433-A1 | POLYMER DEPOSITION AND MODIFICATION OF MEMBRANES FOR FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-03-11 | — | — | US | disclosed |
| US-20100051538-A1 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010006196-A2 | WATER PURIFICATION MEMBRANES WITH IMPROVED FOULING RESISTANCE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-1442006-A2 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | Boehringer Ingelheim Chemicals, Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037843-A2 | PREPARATION OF AMPHETAMINES FROM PHENYLPROPANOLAMINES | BOEHRINGER INGELHEIM CHEMICALS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11123310-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | CYP2D6 15/4885CYP2C9 4/4885CYP2C19 9/4885 |
| US-11717498-B2 | Methods of treatment using amphetamine controlled release, prodrug, and abuse deterrent dosage forms | SLC6A3, SLC6A2, CES2 | CYP2D6 15/4885CYP2C9 5/4885CYP2C19 11/4885 |
| US-20200352883-A1 | METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, SLC6A2, CES2 | CYP2D6 14/4885CYP2C9 5/4885CYP2C19 11/4885 |
| US-20230321010-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | CYP2D6 17/4885CYP2C9 4/4885CYP2C19 8/4885 |
| US-20210030699-A1 | Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms | SLC6A3, SLC6A2, CES2 | CYP2D6 15/4885CYP2C9 5/4885CYP2C19 11/4885 |
| US-12208068-B2 | Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms | SLC6A3, CES2, SLC6A2 | CYP2D6 17/4885CYP2C9 4/4885CYP2C19 8/4885 |
| US-20250213502-A1 | Amphetamine Controlled Release, Prodrug, and Abuse-deterrent Dosage Forms | SLC6A3, CES2, SLC6A2 | CYP2D6 15/4885CYP2C9 4/4885CYP2C19 9/4885 |
| US-20180243241-A1 | AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS | SLC6A3, CES2, SLC6A2 | CYP2D6 15/4885CYP2C9 4/4885CYP2C19 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.